论文部分内容阅读
头颈部鳞状细胞癌(headandnecksquamouscellcarcinoma,HNSCC)是常见的头颈部疾病,其发病率居恶性肿瘤第六位[1]。目前,手术联合放疗、化疗是HNSCC的主要治疗手段。肿瘤免疫治疗是在现代肿瘤免疫学理论的基础上,结合免疫生物学、分子生物学等诸学科的发展而形成的一种治疗手段。因为其效果明显且副作用小,成为综合治疗最主要的辅助手段并广泛应用于临床[2]。T淋巴细胞是肿瘤免疫中发挥效应的主要细胞,而肿瘤细胞或间质所表达的免疫抑制因子可削弱T淋巴细胞功能,导致肿瘤部位的免疫能力下降,从而引起肿瘤细胞的免疫逃避。以免疫抑制因子为靶点的干预方案已成为肿瘤免疫治疗的重要内容之一。本文所述的Galectin-1,正是诱导T细胞凋亡的免疫抑制因子之一。
Head and neck squamous cell carcinoma (head and neck squamous cell carcinoma, HNSCC) is a common head and neck disease, the incidence of ranks sixth in malignant tumors [1]. Currently, surgery combined with radiotherapy and chemotherapy is the main treatment of HNSCC. Tumor immunotherapy is based on the modern theory of tumor immunology, combined with immunobiology, molecular biology and other disciplines developed and formed a treatment. Because of its obvious effect and side effects, becoming the main ancillary treatment of comprehensive treatment and widely used in clinical [2]. T lymphocytes play a role in tumor immunity, and the immunosuppressive factors expressed by tumor cells or interstitium can weaken the function of T lymphocytes, resulting in the decrease of immunity in the tumor site, leading to immune escape of tumor cells. Interventions targeting immunosuppressive agents have become an important part of tumor immunotherapy. Galectin-1, described here, is one of the immunosuppressive factors that induce T-cell apoptosis.